Containing monoclonal antibodies
N335649 · 2023-10-18 — The tariff classification of Hyrimoz® (adalimumab-adaz) Injection in dosage form, from Austria
Hyrimoz® (adalimumab-adaz) Injection is a monoclonal anti-tumor necrosis factor alpha antibody. It is used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis. Hyrimoz® (adalimumab-adaz) Injection will be available in single-dose prefilled pens (40 mg/0.8 mL and 40 mg/0.4 mL) and single-dose prefilled syringes with needle guard (40 mg/0.8 mL and 40 mg/0.4 mL). The applicable subheading for the Hyrimoz® (adalimumab-adaz)…
Not sure this code fits your product? HaiLang AI determines the US HTS code from a description in about a minute.
Classify a product